Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 7/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15101628 | 1.00 | MME (0.45) | MMESMN1; SMN2ACEPOLBSIRT2 | |
| SCHEMBL901542 | 1.00 | MME (0.45) | MMESMN1; SMN2ACEPOLBSIRT2 | |
| SCHEMBL5346764 | 0.97 | SMN1; SMN2 (0.46) | SMN1; SMN2ACEPOLBSIRT2SIRT1 | |
| SCHEMBL21373191 | 0.93 | MME (0.46) | MMEACEPOLBSIRT2SIRT1 | |
| SCHEMBL30313716 | 0.93 | MME (0.46) | MMEACEPOLBSIRT2SIRT1 | |
| SCHEMBL14423531 | 0.91 | MME (0.52) | MMESMN1; SMN2ACEPOLBFOLH1 | |
| SCHEMBL3373746 | 0.91 | MME (0.52) | MMESMN1; SMN2ACEPOLBFOLH1 | |
| SCHEMBL30313811 | 0.90 | MME (0.43) | MMESMN1; SMN2ACEPOLBSIRT2 | |
| SCHEMBL21373190 | 0.90 | MME (0.43) | MMESMN1; SMN2ACEPOLBSIRT2 | |
| SCHEMBL14423532 | 0.90 | SMN1; SMN2 (0.48) | SMN1; SMN2ACEPOLBLMNAHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940929-B2 | Preparation method of high-optical purity N2-[1 -(S)-ethoxycarbonyl-3-phenylpropyl]-N6-trifluoroacetyl-L-lysine | ABA CHEMICALS CORPORATION (CN) | 2015-01-27 | — | — | US | claimed |
| US-20130178651-A1 | PREPARATION METHOD OF HIGH-OPTICAL PURITY N2-[1-(S)-ETHOXYCARBONYL-3-PHENYLPROPYL]-N6-TRIFLUOROACETYL-L-LYSINE | ABA CHEMICALS CORPORATION (CN) | 2013-07-11 | — | — | US | claimed |
| US-7253299-B2 | Process for purifying n2-(1(s)-ethoxycarbonyl-3-phenylpropyl)-n6-thifluoroacetyl-l-lysine | KANEKA CORPORATION (JP) | 2007-08-07 | — | — | US | claimed |
| US-20040147773-A1 | Process for purifying n2-(1(s)-ethoxycarbonyl -3-phenylpropyl)-n6-thifluoroacetyl-l-lysine | KANEKA CORPORATION (JP) | 2004-07-29 | — | — | US | claimed |
| EP-1405845-A1 | METHOD FOR PURIFYING N2-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-N6-TRIFLUOROACETYL-L-LYSINE | KANEKA CORPORATION (JP) | 2004-04-07 | — | — | EP | claimed |
| EP-0239062-B1 | N2-(1-CARBOXY-3-OXO-3-PHENYLPROPYL)-L-LYSINE COMPOUNDS AND THEIR DERIVATIVES | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-05-29 | — | — | EP | claimed |
| EP-0239062-A2 | N2-(1-carboxy-3-oxo-3-phenylpropyl)-L-Lysine compounds and their derivatives | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-09-30 | — | — | EP | claimed |
| JP-8253497-A | — | — | None | — | — | JP | disclosed |
| EP-3543225-B1 | METHOD FOR PREPARING LISINOPRIL INTERMEDIATE | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2023-01-04 | — | — | EP | disclosed |
| CN-113698313-A | Method for recovering lisinopril chiral intermediate | 浙江华海药业股份有限公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-111732627-A | Synthesis method of lisinopril impurity J | 浙江华海药业股份有限公司 | 2020-10-02 | — | — | CN | disclosed |
| US-10633329-B2 | Method for preparing lisinopril intermediate | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-04-28 | — | — | US | disclosed |
| EP-3543225-A1 | METHOD FOR PREPARING LISINOPRIL INTERMEDIATE | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2019-09-25 | — | — | EP | disclosed |
| EP-0903337-A1 | PROCESS FOR THE PREPARATION OF 1-ALKOXYCARBONYL-3-PHENYLPROPYL DERIVATIVES | KANEKA CORPORATION (JP) | 1999-03-24 | — | — | EP | disclosed |
| JP-H08253497-A | PEPTIDE-TYPE COMPOUND | RICHTER GEDEON V G RT | 1996-10-01 | — | — | JP | disclosed |
| EP-0336368-B1 | N2-(1-carboxy-3-phenylpropyl)-L-lysine derivative and process of producing lysinopril using the compound | KANEGAFUCHI CHEMICAL IND (JP) | 1995-02-01 | — | — | EP | disclosed |
| EP-0239062-B1 | N2-(1-CARBOXY-3-OXO-3-PHENYLPROPYL)-L-LYSINE COMPOUNDS AND THEIR DERIVATIVES | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-05-29 | — | — | EP | disclosed |
| EP-0336368-A2 | N2-(1-carboxy-3-phenylpropyl)-L-lysine derivative and process of producing lysinopril using the compound | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-10-11 | — | — | EP | disclosed |
| EP-0239062-A2 | N2-(1-carboxy-3-oxo-3-phenylpropyl)-L-Lysine compounds and their derivatives | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-09-30 | — | — | EP | disclosed |
| EP-0239062-A2 | N2-(1-carboxy-3-oxo-3-phenylpropyl)-L-Lysine compounds and their derivatives | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147773-A1 | Process for purifying n2-(1(s)-ethoxycarbonyl -3-phenylpropyl)-n6-thifluoroacetyl-l-lysine | KARS1, L3MBTL1, PKN2 | MME 751/4885SMN1; SMN2 1082/4885ACE 2862/4885 |
| US-10633329-B2 | Method for preparing lisinopril intermediate | PKLR, PHYKPL, ACE | MME 525/4885SMN1; SMN2 830/4885ACE 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.